Is MDXG or MENS more undervalued in 2026?

CirclFi compares MiMedx Group, Inc (MDXG) and Jyong Biotech Ltd. (MENS) using 13 institutional-grade valuation models. MDXG has a Quality of Company score of 8.6/10 while MENS scores 2.3/10.

Which is a better buy — MDXG or MENS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MDXG and MENS valuations compare?

MDXG at $3.67 and MENS at $2.25 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MDXG vs MENS Valuation Comparison 2026 — Intrinsic Value Analysis

MDXG

Biotechnology

MiMedx Group, Inc

Quality

8.6

out of 10

Value Trap

SAFE

Price

$3.67

Last close

Models

13/13

Active

MENS

Biotechnology

Jyong Biotech Ltd.

Quality

2.3

out of 10

Value Trap

—

Price

$2.25

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	MDXG Fair Value	MDXG Upside	MENS Fair Value	MENS Upside
Bayesian DCF	Intrinsic	$6.90	+88.1%	$0.60	-73.5%
Earnings Power Value	Intrinsic	$1.47	-59.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$6.05	+64.8%	$0.17	-92.1%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MDXG vs MENS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MDXG vs MENS — Which Stock Is More Undervalued?

MDXG scores higher with a 8.6/10 quality rating vs MENS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MiMedx Group, Inc (MDXG) and Jyong Biotech Ltd. (MENS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MDXG currently trades at $3.67 with a QOC of 8.6/10, while MENS trades at $2.25 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).